Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 20, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2025

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab

Dexamethasone 20 mg/d, on the same day of daratumumab injection; Mitoxantrone hydrochloride liposome injection: 20 mg/m2, d1; Daratumumab: 16 mg/Kg, once a week for the first 8 weeks; then changed to once every two weeks; Each cycle is 4 weeks long and the maximum number of cycles is 6.

Trial Locations (1)

Unknown

RECRUITING

Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

lead

Second Affiliated Hospital of Soochow University

OTHER